Introduction and objective:
Arterial hypertension affects approximately 12 million people in Poland, with control rates remaining suboptimal due to therapeutic inertia and treatment non-adherence. The study analyzes contemporary management approaches based on the latest guidelines and clinical evidence, specifically focusing on the benefits of early single-pill combination implementation and treatment optimization within the Polish population.

Review methods:
A review of 26 sources published between 2018–2026 was conducted utilizing PubMed, Google Scholar, and official databases of various scientific societies. Key words focused on combination pharmacotherapy, blood pressure variability, and adherence barriers. Inclusion criteria encompassed recent clinical guidelines, individual patient data meta-analyses, and relevant epidemiological studies.

Brief description of the state of knowledge:
Poland exhibits significant regional disparities and low treatment efficacy. Modern diagnostics emphasize the stabilization of diurnal blood pressure fluctuations to ensure organ protection and cognitive function preservation. Management is anchored in early combination therapy and novel active substances to mitigate therapeutic inertia. Non-adherence, driven by complex dosing schedules and fear of polypharmacy, remains a primary barrier; therefore, single pill combinations represent the gold standard for enhancing physician-patient cooperation.

Summary:
Implementing early combination therapy represents a public health priority in Poland. Novel treatment regimens offer high efficacy while minimizing adverse effects. Long-term therapeutic success depends on bridging the current gap between clinical guidelines and daily practice, supported by intensive patient education.